TLSI TriSalus Life Sciences, Inc.
Healthcare$3.22-1.23%ClosedMarket Cap: $122.1M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
13.12
P/S
2.75
EV/EBITDA
-3.14
DCF Value
$-113.09
FCF Yield
-16.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
85.1%
Operating Margin
-62.4%
Net Margin
-60.9%
ROE
162.6%
ROA
-38.5%
ROIC
-47.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $8.9M | 86.2% | $-8.4M | $1.5M | $— | — |
| Q4 null | $13.2M | 86.7% | $-3.3M | $-9.8M | $— | — |
| FY null | $45.2M | 84.6% | $-26.9M | $-39.2M | $— | — |
| Q3 null | $11.6M | 83.5% | $-9.0M | $-10.8M | $— | — |
| Q2 null | $11.2M | 83.9% | $-7.3M | $-8.3M | $— | — |
| Q1 null | $9.2M | 83.7% | $-7.3M | $-10.4M | $— | — |
| Q4 null | $8.3M | 85.3% | $-7.6M | $-10.1M | $— | — |
| FY null | $29.4M | 86.1% | $-36.2M | $-33.2M | $— | — |
| Q3 null | $7.3M | 86.3% | $-8.7M | $-2.4M | $— | — |
| Q2 null | $7.4M | 87.6% | $-8.2M | $-4.3M | $— | — |
| Q1 null | $6.5M | 85.0% | $-11.7M | $-13.2M | $— | — |
| Q4 2023 | $5.7M | 89.8% | $-14.1M | $-35.5M | $-1.34 | — |